Might dolutegravir be part of a functional cure for HIV?

Can J Microbiol. 2016 May;62(5):375-82. doi: 10.1139/cjm-2015-0725. Epub 2016 Jan 27.

Abstract

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.

Keywords: HIV; VIH; cure; dolutegravir; dolutégravir; drug resistance; remède; résistance aux médicaments.

Publication types

  • Review

MeSH terms

  • Drug Resistance, Viral
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / therapeutic use*
  • HIV-1
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Oxazines
  • Piperazines
  • Pyridones

Substances

  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir